Comparative Efficacy and Safety of Resmetirom and Efruxifermin for Metabolic Dysfunction‐Associated Steatohepatitis: A Network Meta‐Analysis of Randomized Controlled Trials
Key Points
This research compares the effectiveness and safety of resmetirom and efruxifermin for treating metabolic dysfunction-associated steatohepatitis.
Conducted a network meta-analysis of randomized controlled trials
Compared the effects on MRI-PDFF and AST
Assessed safety outcomes between the two interventions
Efruxifermin showed a slightly greater effect on MRI-PDFF
Efruxifermin demonstrated more favorable safety outcomes compared to resmetirom
Abstract
Efruxifermin demonstrated a slightly greater effect on MRI-PDFF and AST, along with more favourable safety outcomes.
Comparative Efficacy and Safety of Resmetirom and Efruxifermin for Metabolic Dysfunction‐Associated Steatohepatitis: A Network Meta‐Analysis of Randomized Controlled Trials | Synapse